Therapeutic targets of renin-angiotensin system in ocular disorders

Journal of Current Ophthalmology

Volumn 29, Issue 1, 2017, Pages 7-16

  Choudhary, Rajesh ^a   Kapoor, Mandeep Singh ^a   Singh, Amrita ^a   Bodakhe, Surendra H ^a  

^a GURU GHASIDAS UNIVERSITY   (India)

Author keywords

(Pro) renin receptor; Angiotensin II; Angiotensin II type 1 receptor; Ocular disorders; Ocular renin angiotensin system

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN I; ANGIOTENSIN II; ANGIOTENSINOGEN; CALCIUM ION; DIMINAZENE ACETURATE; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; G PROTEIN COUPLED RECEPTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; MAS RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; PRORENIN; PRORENIN RECEPTOR; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; RENIN; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG; VASCULOTROPIN;

AGE RELATED MACULAR DEGENERATION; CATARACT; CHOROID; CILIARY BODY; DIABETIC RETINOPATHY; DISEASE COURSE; DRUG TARGETING; EYE DISEASE; EYE PROTECTION; GLAUCOMA; HUMAN; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PROTEIN EXPRESSION; REGULATORY MECHANISM; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RETINA; REVIEW; SIGNAL TRANSDUCTION; UVEITIS;

EID: 85008958488     PISSN: None     EISSN: 24522325     Source Type: Journal    
DOI: 10.1016/j.joco.2016.09.009     Document Type: Review

References (148)

1. 1 Fyhrquist, F., Saijonmaa, O., Renin-angiotensin system revisited. J Intern Med 264 (2008), 224–236.
2. 2 White, A.J.R., Cheruvu, S.C., Sarris, M., et al. Expression of classical components of the renin-angiotensin system in the human eye. J Renin Angiotensin Aldosterone Syst 16 (2015), 59–66.
3. 3 Cheng, Z.J., Vapaatalo, H., Mervaala, E., Angiotensin II and vascular inflammation. Med Sci Monit 11 (2005), RA194–205.
4. 4 Culman, J., Hohle, S., Qadri, F., et al. Angiotensin as neuromodulator/neurotransmitter in central control of body fluid and electrolyte homeostasis. Clin Exp Hypertens 17 (1995), 281–293.
5. 5 Qi, G.M., Jia, L.X., Li, X.L., Du, J., Adiponectin suppresses angiotensin II-induced inflammation and cardiac fibrosis through activation of macrophage autophagy. Endocrinology 155 (2014), 2254–2265.
6. 6 Chung, O., Kuhl, H., Stoll, M., Unger, T., Physiological and pharmacological implications of AT1 versus AT2 receptors. Kidney Int 67 (1998), S95–S99.
7. 7 Cao, Z., Kelly, D.J., Cox, A., et al. Angiotensin type 2 receptor is expressed in the adult rat kidney and promotes cellular proliferation and apoptosis. Kidney Int 58 (2000), 2437–2451.
8. 8 Levy, B.I., Benessiano, J., Henrion, D., et al. Chronic blockade of AT2-subtype receptors prevents the effect of angiotensin II on the rat vascular structure. J Clin Invest 98 (1996), 418–425.
9. 9 Sarlos, S., Rizkalla, B., Moravski, C.J., Cao, Z., Cooper, M.E., Wilkinson-Berka, J.L., Retinal angiogenesis is mediated by an interaction between the angiotensin type 2 receptor, VEGF, and angiopoietin. Am J Pathol 163 (2003), 879–887.
10. 10 Rong, P., Wilkinson-Berka, J.L., Skinner, S.L., Control of renin secretion from adrenal gland in transgenic Ren-2 and normal rats. Mol Cel Endocrinol 173 (2001), 203–212.
11. 11 Wilkinson-Berka, J.L., Kelly, D.J., Rong, P., Campbell, D.J., Skinner, S.L., Characterization of a thymic renin-angiotensin system in the transgenic m(Ren-2)27 rat. Mol Cel Endocrinol 194 (2002), 201–209.
12. 12 Kurihara, T., Ozawa, Y., Ishida, S., Okano, H., Tsubota, K., Renin angiotensin system hyperactivation can induce inflammation and retinal neural dysfunction. Int J Inflam, 581695, 2012, 14.
13. 13 Danser, A.H., Van den Dorpel, M.A., Deinum, J., et al. Renin, prorenin, and immunoreactive renin in vitreous fluid from eyes with and without diabetic retinopathy. J Clin Endocrinol Metab 68 (1989), 160–167.
14. 14 Sramek, S.J., Wallow, I.H., Day, R.P., Ehrlich, E.N., Ocular renin-angiotensin: immunohistochemical evidence for the presence of prorenin in eye tissue. Invest Ophthalmol Vis Sci 29 (1988), 1749–1752.
15. 15 Wallow, I.H.L., Sramek, S.J., Bindley, C.D., Darjatmoko, S.R., Gange, S.J., Ocular rennin angiotensin: immunocytochemical localization of prorenin. Curr Eye Res 12 (1993), 945–950.
16. 16 Berka, J.L., Stubbs, A.J., Wang, D.J., et al. Renin-containing Muller cells of the retina display endocrine features. Invest Ophthalmol Vis Sci 36 (1995), 1450–1458.
17. 17 Brandt, C.R., Pumfery, A.M., Micales, B., et al. Renin mRNA is synthesized locally in rat ocular tissues. Curr Eye Res 13 (1994), 755–763.
18. 18 Milenkovic, V.M., Brockmann, M., Meyer, C., et al. Regulation of the renin expression in the retinal pigment epithelium by systemic stimuli. Am J Physiol Ren Physiol 299 (2010), F396–F403.
19. 19 Ramirez, M., Davidson, E.A., Luttenauer, L., et al. J Ocul Pharmacol Ther 12 (1996), 299–312.
20. 20 Wagner, J., Jan Danser, A.H., Derkx, F.H., et al. Demonstration of renin mRNA, angiotensinogen mRNA, and angiotensin converting enzyme mRNA expression in the human eye: evidence for an intraocular renin-angiotensin system. Br J Ophthalmol 80 (1996), 159–163.
21. 21 Danser, A.H., Derkx, F.H., Admiraal, P.J., Deinum, J., De Jong, P.T., Schalekamp, M.A., Angiotensin levels in the eye. Invest Ophthalmol Vis Sci 35 (1994), 1008–1018.
22. 22 Goel, A.K., Jabbour, N.M., Vitreous level of angiotensin-II in patients with diabetic retinopathy. Invest Ophthalmol Vis Sci, 32, 1991, 1027.
23. 23 Savaskan, E., Loffler, K., Meier, F., Muller, F.S., Flammer, J., Meyer, P., Immunohistochemical localization of angiotensin-converting enzyme, angiotensin II and angiotensin AT1 receptor in human ocular tissues. Ophthalmic Res 36 (2004), 312–320.
24. 24 Senanayake, P., Drazba, J., Shadrach, K., et al. Angiotensin II and its receptor subtypes in the human retina. Invest Ophthalmol Vis Sci 48 (2007), 3301–3311.
25. 25 Holappa, M., Valjakka, J., Vaajanen, A., Angiotensin(1–7) and ACE2, “The hot spots” of renin-angiotensin system, detected in the human aqueous humor. Open Ophthalmol J 9 (2015), 28–32.
26. 26 Ferrari, D.G., Ryan, J.W., Rockwood, E.J., Davis, E.B., Anderson, D.R., Angiotensin-converting enzyme in bovine, feline, and human ocular tissues. Invest Ophthalmol Vis Sci 29 (1988), 876–881.
27. 27 Geng, L., Persson, K., Nilsson, S.F.E., Angiotensin converting enzyme (ACE) activity in porcine ocular tissue: effects of diet and ACE inhibitors. J Pharm Ther 19 (2003), 589–596.
28. 28 Igic, R., Kojovic, V., Angiotensin I converting enzyme (kininase II) in ocular tissues. Exp Eye Res 30 (1980), 299–303.
29. 29 Ikemoto, F., Yamamoto, K., Renin angiotensin system in the aqueous humor of rabbits, dogs and monkeys. Exp Eye Res 27 (1978), 723–725.
30. 30 Immonen, I., Friberg, K., Sorsila, R., Fyhrquist, F., Concentration of angiotensin-converting enzyme in tears of patients with sarcoidosis. Acta Ophthalmol Copenh 65 (1987), 27–29.
31. 31 Kida, T., Ikeda, T., Nishimura, M., et al. Renin-angiotensin system in proliferative diabetic retinopathy and its gene expression in cultured human Muller cells. J Ophthalmol 47 (2003), 36–41.
32. 32 Maruichi, M., Oku, H., Takai, S., et al. Measurement of activities in two different angiotensin II generating systems, chymase and angiotensin-converting enzyme, in the vitreous fluid of vitreoretinal diseases: a possible involvement of chymase in the pathogenesis of macular hole patients. Curr Eye Res 29 (2004), 321–325.
33. 33 Sharma, O.P., Vita, J.B., Determination of angiotensin converting enzyme in tears: a noninvasive test for evaluation of ocular sarcoidosis. Arch Ophthalmol 101 (1983), 559–561.
34. 34 Shiota, N., Saegusa, Y., Nishimura, K., Miyazaki, M., Angiotensin II generating system in dog and monkey ocular tissues. Clin Exp Pharmacol Physiol 24 (1997), 243–248.
35. 35 Strittmatter, S.M., Braas, K.M., Snyder, S.H., Localisation of angiotensin converting enzyme in the ciliary epithelium of the rat eye. Invest Ophthalmol Vis Sci 30 (1989), 2209–2214.
36. 36 Vita, J.B., Anderson, J.A., Hulem, C.D., Irving, H.L., Angiotensin converting enzyme activity in ocular fluids. Invest Ophthalmol Vis Sci 20 (1981), 255–257.
37. 37 Ward, P.E., Stewart, T.A., Hammon, K.J., Reynolds, R.C., Igic, R., Angiotensin I converting enzyme (kininase II) in isolated retinal microvessels. Life Sci 24 (1979), 1419–1424.
38. 38 Weinreb, R.N., Sandman, R., Ryder, M.I., Friberg, T.R., Angiotensin converting enzyme activity in human aqueous humor. Arch Ophthalmol 103 (1985), 34–36.
39. 39 Zhang, J.Z., Gao, L., Windness, M., Xi, X., Kern, T., Captopril inhibits glucose accumulation in retinal cells in diabetes. Invest Ophthalmol Vis Sci 44 (2003), 4001–4005.
40. 40 Luhtala, S., Vaajanen, A., Oksala, O., Valjakka, J., Vapaatalo, H., Activities of angiotensin-converting enzymes ACE1 and ACE2 and inhibition by bioactive peptides in porcine ocular tissues. J Ocul Pharmacol Ther 25 (2009), 23–28.
41. 41 Tikellis, C., Johnston, C.I., Forbes, J.M., et al. Identification of angiotensin converting enzyme 2 in the rodent retina. Curr Eye Res 29 (2004), 419–427.
42. 42 Satofuka, S., Ichihara, A., Nagai, N., et al. Suppression of ocular inflammation in endotoxin-induced uveitis by inhibiting nonproteolytic activation of prorenin. Invest Ophthalmol Vis Sci 47 (2006), 2686–2692.
43. 43 Wilkinson-Berka, J.L., Miller, A.G., Fletcher, E.L., Prorenin and the (pro) renin receptor: do they have a pathogenic role in the retina?. Front Biosci Elite Ed 2 (2010), 1054–1064.
44. 44 Buschini, E., Fea, A.M., Lavia, C.A., et al. Recent developments in the management of dry age-related macular degeneration. Clin Ophthalmol 9 (2015), 563–574.
45. 45 Downie, L.E., Vessey, K., Miller, A., et al. Neuronal and glial cell expression of angiotensin II type 1 (AT1) and type 2 (AT2) receptors in the rat retina. Neuroscience 161 (2009), 195–213.
46. 46 Fletcher, E.L., Phipps, J.A., Ward, M.M., Vessey, K.A., Wilkinson-Berka, J.L., The renin-angiotensin system in retinal health and disease: its influence on neurons, glia and the vasculature. Prog Retin Eye Res 29 (2010), 284–311.
47. 47 Murata, M., Nakagawa, M., Takahashi, S., Expression and localization of angiotensin II type I receptor mRNA in rat ocular tissues. Ophthalmologica 211 (1997), 384–386.
48. 48 Wheeler-Schilling, T.H., Kohler, K., Sautter, M., Guenther, E., Angiotensin II receptor subtype gene expression and cellular localization in the retina and non-neuronal ocular tissues of the rat. Euro J Neurosci 11 (1999), 3387–3394.
49. 49 Vaajanen, A., Vapaatalo, H., Kautiainen, H., Oksala, O., Angiotensin (1–7) reduces intraocular pressure in the normotensive rabbit eye. Invest Ophthalmol Vis Sci 49 (2008), 2557–2562.
50. 50 Vaajanen, A., Lakkisto, P., Virtanen, I., et al. Angiotensin receptors in the eyes of arterial hypertensive rats. Acta Ophthalmol 88 (2010), 431–438.
51. 51 Vaajanen, A., Kalesnykas, G., Vapaatalo, H., Uusitalo, H., The expression of Mas-receptor of the renin–angiotensin system in the human eye. Graefes Arch Clin Exp Ophthalmol 253 (2015), 1053–1059.
52. 52 Igic, R., Robinson, C.J.G., Erdos, E.G., Angiotensin I converting enzyme activity in the choroid plexus and in the retinal. Buckley, J.P., Ferrario, C.M., (eds.) Central actions of Angiotensin and Related Hormones, 1977, Pergamon Press, New York, 23–27.
53. 53 Kramkowski, K., Mogielnicki, A., Buczko, W., The physiological significance of the alternative pathways of angiotensin II production. J Physiol Pharmacol 57 (2006), 529–539.
54. 54 Santos, R.A., Simoes e Silva, A.C., Maric, C., et al. Angiotensin (1–7) is an endogenous ligand for the G-protein-coupled receptor Mas. Proc Natl Acad Sci USA 8 (2003), 8258–8263.
55. 55 Kostenis, E., Milligan, G., Christopoulos, A., et al. G-protein-coupled receptor Mas is a physiological antagonist of the angiotensin II type I receptor. Circulation 111 (2005), 1806–1813.
56. 2+ signaling in the retinal pigment epithelium: role of angiotensin-receptor-associated-protein and TRPV2 channel. PLoS One, 7, 2012, e49624.
57. 57 Fellner, S.K., Arendshorst, W.J., Angiotensin II Ca2+signaling in rat afferent arterioles: stimulation of cyclic ADP ribose and IP3 pathways. Am J Physiol Ren Physiol 288 (2005), F785–F791.
58. 58 Boehm, I.H., Sosna, T., Andersen, H.L., Porta, M., The eyes in diabetes and diabetes through the eyes. Diabetes Res Clin Prac 78S (2007), S51–S58.
59. 59 Tarr, J.M., Kaul, K., Chopra, M., Kohner, E.M., Chibber, R., Pathophysiology of diabetic retinopathy. ISRN Ophthalmol 34 (2013), 35–60.
60. 60 Funastu, H., Yamashita, H., Pathogenesis of diabetic retinopathy and the renin angiotensin system. Ophthalmic Physiol Opt 23 (2003), 495–501.
61. 61 Gilbert, R.E., Kelly, D.J., Cox, A.J., et al. Angiotensin converting enzyme inhibition reduces retinal overexpression of vascular endothelial growth factor and hyperpermeability in experimental diabetes. Diabetologia 43 (2000), 1360–1367.
62. 62 Moravski, C.J., Kelly, D.J., Cooper, M.E., et al. Retinal neovascularization is prevented by blockade of the renin-angiotensin system. Hypertension 36 (2000), 1099–1104.
63. 63 Nagisa, Y., Shintani, A., Nakagawa, S., The angiotensin II receptor antagonist candesartan cilexetil (TCV-116) ameliorates retinal disorders in rats. Diabetologia 44 (2001), 883–888.
64. 64 Sjolie, A.K., Chaturvedi, N., The retinal renin-angiotensin system: implications for therapy in diabetic retinopathy. J Hum Hypertens 16 (2002), S42–S46.
65. 65 Kurihara, T., Ozawa, Y., Nagai, N., et al. Angiotensin II type 1 receptor signaling contributes to synaptophysin degradation and neuronal dysfunction in the diabetic retina. Diabetes 57 (2008), 2191–2198.
66. 66 Pons, M., Cousins, S.W., Alcazar, O., Striker, G.E., Marin-Castano, M.E., Angiotensin II-induced MMP-2 activity and MMP-14 and basigin protein expression are mediated via angiotensin II receptor type 1-mitogen-activated protein kinase 1 pathway in retinal pigment epithelium. Am J Pathol 178 (2011), 2665–2681.
67. 67 Nagai, N., Izumi-Nagai, K., Oike, Y., et al. Suppression of diabetes induced retinal inflammation by blocking the angiotensin II type 1 receptor or its downstream nuclear factor-kappaB pathway. Invest Ophthalmol Vis Sci 48 (2007), 4342–4350.
68. 68 Wilkinson-Berka, J.L., Campbell, D.J., (Pro)renin receptor: a treatment target for diabetic retinopathy?. Diabetes 58 (2009), 1485–1487.
69. 69 Ola, M.S., Ahmed, M., Abuohashish, H.M., Al-Rejaie, S.S., Alhomida, A.S., Telmisartan ameliorates neurotrophic support and oxidative stress in the retina of streptozotocin-induced diabetic rats. Neurochem Res 38 (2013), 1572–1579.
70. 70 Miller, A.G., Tan, G., Binger, B.J., et al. Candesartan attenuates diabetic retinal vascular pathology by restoring glyoxalase-I function. Diabetes 59 (2010), 3208–3215.
71. 71 Wilkinson-Berka, J.L., Angiotensin and diabetic retinopathy. Int J Biochem Cell Biol 38 (2006), 752–765.
72. 72 Wilkinson-Berka, J.L., Prorenin and the (pro)renin receptor in ocular pathology. Am J Pathol 173 (2008), 1591–1594.
73. 73 Ichihara, A., Hayashi, M., Kaneshiro, Y., et al. Inhibition of diabetic nephropathy by a decoy peptide corresponding to the “handle” region for nonproteolytic activation of prorenin. J Clin Invest 114 (2004), 1128–1135.
74. 74 Nguyen, G., Delarue, F., Burckle, C., Bouzhir, L., Giller, T., Sraer, J.D., Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin. J Clin Invest 109 (2002), 1417–1427.
75. 75 Huang, Y., Noble, N.A., Zhang, J., Xu, C., Border, W.A., Renin-stimulated TGF-beta1 expression is regulated by a mitogen-activated protein kinase in mesangial cells. Kidney Int 72 (2007), 45–52.
76. 76 Kaneshiro, Y., Ichihara, A., Sakoda, M., et al. Slowly progressive, angiotensin II-independent glomerulosclerosis in human (pro)renin receptor-transgenic rats. J Am Soc Nephrol 18 (2007), 1789–1795.
77. 77 Satofuka, S., Ichihara, A., Nagai, N., et al. Role of nonproteolytically activated prorenin in pathologic, but not physiologic, retinal neovascularization. Invest Ophthalmol Vis Sci 48 (2007), 422–429.
78. 78 Vision 2020: The Right to Sight. Global Initiative for the Elimination of Avoidable Blindness: Action Plan 2006–2011. World Health Organization. http://www.who.int/blindness/Vision2020_report.pdf.
79. 79 Hogeboom, B.I.M., Polak, B.C., Reichert-Thoen, J.W., et al. Angiotensin converting enzyme inhibiting therapy is associated with lower vitreous vascular endothelial growth factor concentrations in patients with proliferative diabetic retinopathy. Diabetologia 45 (2002), 203–209.
80. 80 Zheng, Z., Chen, H., Ke, G., et al. Protective effect of perindopril on diabetic retinopathy is associated with decreased vascular endothelial growth factor-to-pigment epithelium-derived factor ratio: involvement of a mitochondria-reactive oxygen species pathway. Diabetes 58 (2009), 954–964.
81. 81 Sugiyama, T., Okuno, T., Fukuhara, M., et al. Angiotensin II receptor blocker inhibits abnormal accumulation of advanced glycation end products and retinal damage in a rat model of type 2 diabetes. Exp Eye Res 85 (2007), 406–412.
82. 82 White, A.J.R., Heller, J.P., Leung, J., Tassoni, A., Martin, K.R., Retinal ganglion cell neuroprotection by an angiotensin II blocker in an ex vivo retinal explant model. J Renin Angiotensin Aldosterone Syst 16 (2015), 1193–1201.
83. 83 Haque, R., Hur, E.H., Farrell, A.N., Iuvone, P.M., Howell, J.C., MicroRNA-152 represses VEGF and TGFβ1 expressions through post-transcriptional inhibition of (Pro)renin receptor in human retinal endothelial cells. Mol Vis 21 (2015), 224–235.
84. 84 Kanda, A., Ishida, S., The vitreous renin–angiotensin system is mediated by soluble (pro)renin receptor in diabetic retinopathy: a new implication of the receptor-associated prorenin system. Taiwan J Ophthalmol 3 (2013), 51–53.
85. 85 Kanda, A., Noda, K., Saito, W., Ishida, S., (Pro)renin receptor is associated with angiogenic activity in proliferative diabetic retinopathy. Diabetologia 55 (2012), 3104–3113.
86. 86 Satofuka, S., Ichihara, A., Nagai, N., et al. (Pro)renin receptor–mediated signal transduction and tissue renin-angiotensin system contribute to diabetes-induced retinal inflammation. Diabetes 58 (2009), 1625–1633.
87. 87 Foureaux, G., Nogueira, B.S., Coutinho, D.C.O., Raizada, M.K., Nogueira, J.C., Ferreira, A.J., Activation of endogenous angiotensin converting enzyme 2 prevents early injuries induced by hyperglycemia in rat retina. Braz J Med Bio Res 48 (2015), 1109–1114.
88. 88 Cullinane, A.B., Leung, P.S., Ortego, J., Coca-Prados, M., Harvey, B.J., Renin-angiotensin system expression and secretory function in cultured human ciliary body non-pigmented epithelium. Br J Ophthalmol 86 (2002), 676–683.
89. 89 Shen, F., Zhang, L., Liu, T., Effects of angiotensin II on the 3H-TdR incorporation and synthesis of collagen in cultured bovine trabecular meshwork cells (article in Chinese). Yan Ke Xue Bao 17 (2001), 209–212.
90. 90 Inoue, T., Yokoyoma, T., Koike, H., The effect of angiotensin II on uveoscleral outflow in rabbits. Curr Eye Res 23 (2001), 139–143.
91. 91 Mehta, A., Iyer, L., Parmar, S., Shah, G., Goyal, R., Oculohypotensive effect of perindopril in acute and chronic models of glaucoma in rabbits. Can J Physiol Pharmacol 88 (2010), 595–600.
92. 92 Shah, G.B., Sharma, S., Mehta, A.A., Goyal, R.K., Oculohypotensive effect of angiotensin-converting enzyme inhibitors in acute and chronic models of glaucoma. J Cardiovasc Pharm 36 (2000), 169–175.
93. 93 Costagliola, C., Verolino, M., de Rosa, M.L., Iaccarino, G., Ciancaglini, M., Mastropasqua, L., Effect of oral losartan potassium on intraocular pressure in normotensive and glaucomatous human subjects. Exp Eye Res 71 (2000), 167–171.
94. 94 Wang, R.F., Podos, S.M., Mittag, T.W., Yokoyoma, T., Effect of CS-088, an angiotensin AT1 receptor antagonist, on intraocular pressure in glaucomatous monkey eyes. Exp Eye Res 80 (2005), 629–632.
95. 95 Lotti, V.J., Pawlowski, N., Prostaglandins mediate the ocular hypotensive action of the angiotensin converting enzyme inhibitor MK-422 (enalaprilat) in African green monkeys. J Ocul Pharmacol 6 (1990), 1–7.
96. 96 Reitsamer, H.A., Kiel, J.W., Relationship between ciliary body blood flow and aqueous production in rabbits. Invest Ophthalmol Vis Sci 44 (2003), 3967–3971.
97. 97 Sharif, N.A., Novel potential treatment modalities for ocular hypertension: focus on angiotensin and bradykinin system axes. J Ocul Pharmacol Ther 31 (2015), 131–145.
98. 98 Nagai, N., Oike, Y., Izumi-Nagai, K., et al. Suppression of choroidal neovascularization by inhibiting angiotensin-converting enzyme: minimal role of bradykinin. Invest Ophthalmol Vis Sci 48 (2007), 2321–2326.
99. 99 Ishida, S., Lifestyle-related diseases and anti-aging ophthalmology: suppression of retinal and choroidal pathologies by inhibiting renin-angiotensin system and inflammation. Nihon Ganka Gakkai Zasshi 113 (2009), 403–422.
100. 100 Satofuka, S., Ichihara, A., Nagai, N., et al. (Pro)renin receptor promotes choroidal neovascularization by activating its signal transduction and tissue renin angiotensin system. Am J Pathol 173 (2008), 1911–1918.
101. 101 Nagai, N., Oike, Y., Izumi-Nagai, K., et al. Angiotensin II type 1 receptor-mediated inflammation is required for choroidal neovascularization. Arterioscler Thromb Vasc Bio 26 (2006), 2252–2259.
102. 102 Nagai, N., Oike, Y., Noda, N., et al. Suppression of ocular inflammation in endotoxin-induced uveitis by blocking the angiotensin II type 1 receptor. Invest Ophthalmol Vis Sci 46 (2005), 2925–2931.
103. 103 Okunuki, Y., Usui, Y., Nagai, N., et al. Suppression of experimental autoimmune uveitis by angiotensin II type 1receptor blocker telmisartan. Invest Ophthalmol Vis Sci 50 (2009), 2255–2261.
104. 104 Kurihara, T., Ozawa, Y., Shinoda, K., et al. Neuroprotective effects of angiotensin II type 1 receptor (AT1R) blocker, telmisartan, via modulating AT1R and AT2R signaling in retinal inflammation. Invest Ophthalmol Vis Sci 47 (2006), 5545–5552.
105. 105 Miyazaki, A., Kitaichi, N., Ohgami, K., et al. Anti-inflammatory effect of angiotensin type 1 receptor antagonist on endotoxin-induced uveitis in rats. Graefe's Arch Clin Exp Ophthalmol 246 (2008), 747–757.
106. 106 Nagai, N., Noda, K., Urano, T., et al. Selective suppression of pathologic, but not physiologic, retinal neovascularization by blocking the angiotensin II type 1 receptor. Invest Ophthalmol Vis Sci 46 (2005), 1078–1084.
107. 107 Qiu, Y., Shil, P.K., Zhu, P., et al. Angiotensin-converting enzyme 2 (ACE2) activator dize ameliorates endotoxin-induced uveitis in mice. Invest Ophthalmol Vis Sci 55 (2014), 3809–3818.
108. 108 Khan, S.A., Choudhary, R., Singh, A., Bodakhe, S.H., Hypertension potentiates cataractogenesis in rat eye through modulation of oxidative stress and electrolyte homeostasis. J Curr Ophthalmol 28 (2016), 123–130.
109. 109 Jablecka, A., Czaplicka, E., Olszewski, J., Bogdanski, P., Krauss, H., Smolarek, I., Influence of selected angiotensin-converting enzyme inhibitors on alloxan-induced diabetic cataract in rabbits. Med Sci Monit 15 (2009), BR334–338.
110. 110 Langade, D.G., Rao, G., Girme, R.C., Patki, P.S., Bulakh, P.M., In vitro prevention by ACE inhibitors of cataract induced by glucose. Indian J Pharmacol 38 (2006), 107–110.
111. 111 Harindhanavudhi, T., Mauer, M., Klein, R., Zinman, B., Sinaiko, A., Caramori, M.L., Benefits of renin-angiotensin blockade on retinopathy in type 1 diabetes vary with glycemic control. Diabetes Care 34 (2011), 1838–1842.
112. 112 Sjolie, A.K., Dodson, P., Hobbs, F.R.R., Does renin-angiotensin system blockade have a role in preventing diabetic retinopathy? A clinical review. Int J Clin Pract 65 (2011), 148–153.
113. 113 Otani, A., Takagi, H., Suzuma, K., Honda, Y., Angiotensin II potentiates vascular endothelial growth factor-induced angiogenic activity in retinal microcapillary endothelial cells. Circ Res 82 (1998), 619–628.
114. 114 Otani, A., Takagi, H., Oh, H., et al. Angiotensin II-stimulated potentiates vascular endothelial growth factor expression in bovine retinal pericytes. Invest Ophthalmol Vis Sci 41 (2000), 1192–1199.
115. 115 Chaturvedi, N., Modulation of renin-angiotensin system and retinopathy. Heart 84 (2000), i29–i31.
116. 116 Clermont, A., Bursell, S.E., Feener, E.P., Role of the angiotensin II type 1 receptor in the pathogenesis of diabetic retinopathy: effects of blood pressure control and beyond. J Hypertens 24 (2006), S73–S80.
117. 117 Mauer, M., Zinman, B., Gardiner, R., et al. Renal and retinal effects of enalapril and losartan in type 1 diabetes. N Engl J Med 361 (2009), 40–51.
118. 118 Wilkinson-Berka, J.L., Tan, G., Jaworski, K., Ninkovic, S., Valsartan but not atenolol improves vascular pathology in diabetic ren-2 rat retina. Am J Hypertens 20 (2007), 423–430.
119. 119 Fernandez, L.A., Twickler, J., Mead, A., Neovascularization produced by angiotensin II. J Lab Clin Med 105 (1985), 141–145.
120. 120 Aiello, L.P., Bursell, S.E., Clermont, A., et al. Vascular endothelial growth factor-induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective beta-isoform-selective inhibitor. Diabetes 46 (1997), 1473–1480.
121. 121 Funatsu, H., Yamashita, H., Ikeda, T., Nakanishi, Y., Kitano, S., Hori, S., Angiotensin II and vascular endothelial growth factor in the vitreous fluid of patients with diabetic macular edema and other retinal disorders. Am J Ophthalmol 133 (2002), 537–543.
122. 122 Funatsu, H., Yamashita, H., Nakanishi, Y., Hori, S., Angiotensin II and vascular endothelial growth factor in the vitreous fluid of patients with proliferative diabetic retinopathy. Bri J Ophthalmol 86 (2002), 311–315.
123. 123 Schiffman, R.M., Fisher, L., Nussbaum, J., Edwards, P., Scicli, G., Prorenin and renin levels in the vitreous of human eyes with and without proliferative diabetic retinopathy. Invest Ophthalmol Vis Sci, 33, 1992, 1362.
124. 124 Pradhan, R., Fong, D., March, C., et al. Angiotensin-converting enzyme inhibition for the treatment of moderate to severe diabetic retinopathy in normotensive type 2 diabetic patients a pilot study. J Diabetes Complications 16 (2002), 377–381.
125. 125 Chaturvedi, N., Porta, M., Klein, R., et al. Direct programme study group. Effect of candesartan on prevention (Direct Prevent 1) and progression (Direct Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trials. Lancet 372 (2008), 1394–1402.
126. 126 Gilbert, R.E., Vranes, D., Berka, J.L., et al. Vascular endothelial growth factor and its receptors in control and diabetic rat eyes. Lab Invest 78 (1998), 1017–1027.
127. 127 Vaajanen, A., Vapaatalo, H., Local ocular renin–angiotensin system – a target for glaucoma therapy?. Basic Clin Pharmacol Toxicol 9 (2011), 217–224.
128. 128 Bathija, R., Gupta, N., Zangwill, L., Weinreb, R.N., Changing definition of glaucoma. J Glaucoma 7 (1998), 165–169.
129. 129 Bonomi, L., Marchini, G., Marraffa, M., Bernardy, P., Morbio, R., Varotto, A., Vascular risk factors for primary open angle glaucoma: the Enga-Neumarkt study. Ophthalmology 107 (2000), 1287–1293.
130. 130 Drance, S., Anderson, D.R., Schulzer, M., Collaborative normal-tension glaucoma study group. Risk factors for progression of visual field abnormalities in normal-tension glaucoma. Am J Ophthalmol 131 (2001), 699–708.
131. 131 Flammer, J., Haefl Iger, I.Q., Orgul, S., Resink, T., Vascular dysregulation: a principal risk factor for glaucomatous damage?. J Glaucoma 8 (1999), 212–219.
132. 132 Quigley, H.A., Pitha, I.F., Welsbie, D.S., et al. Losartan treatment protects retinal ganglion cells and alters scleral remodeling in experimental glaucoma. PLoS One, 10, 2015, e0141137, 10.1371/journal.pone.0141137.
133. 133 Yang, H., Hirooka, K., Fukuda, K., Shiraga, F., Neuroprotective effects of angiotensin II type 1 receptor blocker in a rat model of chronic glaucoma. Invest Ophthalmol Vis Sci 50 (2009), 5800–5804.
134. 134 Espinosa-Heidmann, D.G., Suner, I.J., Hernandez, E.P., Monroy, D., Csaky, K.G., Cousins, S.W., Macrophage depletion diminishes lesion size and severity in experimental choroidal neovascularization. Invest Ophthalmol Vis Sci 44 (2003), 3586–3592.
135. 135 Sakurai, E., Anand, A., Ambati, B.K., Rooijen, V.N., Ambati, J., Macrophage depletion inhibits experimental choroidal neovascularization. Invest Ophthalmol Vis Sci 44 (2003), 3578–3585.
136. 136 Tsutsumi, C., Sonoda, K.H., Egashira, K., et al. The critical role of ocular-infiltrating macrophages in the development of choroidal neovascularization. J Leukoc Biol 74 (2003), 25–32.
137. 137 Gragoudas, E.S., Adamis, A.P., Cunningham, E.T., Feinsod, M., Guyer, D.R., Pegaptanib for neovascular age-related macular degeneration. New Engl J Med 351 (2004), 2805–2816.
138. 138 Rosenfeld, P.J., Brown, D.M., Heier, J.S., et al. Ranibizumab for neovascular age-related macular degeneration. New Engl J Med 355 (2006), 1419–1431.
139. 139 Praddaude, F., Cousins, S.W., Pecher, C., Marin-Castano, M.E., Angiotensin II induced hypertension regulates AT1 receptor subtypes and extracellular matrix turnover in mouse retinal pigment epithelium. Exp Eye Res 89 (2009), 109–118.
140. 140 Striker, G.E., Praddaude, F., Alcazar, O., Cousins, S.W., Marin-Castano, M.E., Regulation of angiotensin II receptors and extracellular matrix turnover in human retinal pigment epithelium: role of angiotensin II. Am J Physiol Cell Physiol 295 (2008), C1633–C1646.
141. 141 Nabah, Y.N., Mateo, T., Estelles, R., et al. Angiotensin II induces neutrophil accumulation in vivo through generation and release of CXC chemokines. Circulation 110 (2004), 3581–3586.
142. 142 Alcazar, O., Cousins, S.W., Striker, G.E., Marin-Castano, M.E., (Pro)renin receptor is expressed in human retinal pigment epithelium and participates in extracellular matrix remodeling. Exp Eye Res 89 (2009), 638–647.
143. 143 Nahmod, K.A., Vermeulen, M.E., Raiden, S., et al. Control of dendritic cell differentiation by angiotensin II. FASEB J 17 (2003), 491–493.
144. 144 Pastore, L., Tessitore, A., Martinotti, S., et al. Angiotensin II stimulates intercellular adhesion molecule-1 (ICAM-1) expression by human vascular endothelial cells and increases soluble ICAM-1 release in vivo. Circulation 100 (1999), 1646–1652.
145. 145 Gupta, S.K., Selvan, V.K., Agrawal, S.S., Saxena, R., Advances in pharmacological strategies for the prevention of cataract development. Indian J Ophthalmol 57 (2009), 175–183.
146. 146 Sabanayagam, C., Wang, J.J., Mitchell, P., et al. Metabolic syndrome components and age-related cataract: the Singapore Malay eye study. Invest Ophthalmol Vis Sci 52 (2011), 2397–2404.
147. 147 Phipps, J.A., Wilkinson-Berka, J.L., Fletcher, E.L., Retinal dysfunction in diabetic ren-2 rats is ameliorated by treatment with valsartan but not atenolol. Invest Ophthalmol Vis Sci 48 (2007), 927–934.
148. 148 Strain, W.D., Chaturvedi, N., The renin-angiotensin-aldosterone system and the eye in diabetes. J Renin Angiotensin Aldosterone Syst 3 (2002), 243–246.